Osher Van de Voorde Investment Management increased its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 1.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 179,465 shares of the biopharmaceutical company’s stock after purchasing an additional 2,620 shares during the quarter. Bristol-Myers Squibb accounts for 3.7% of Osher Van de Voorde Investment Management’s investment portfolio, making the stock its 16th largest position. Osher Van de Voorde Investment Management’s holdings in Bristol-Myers Squibb were worth $9,101,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Bristol-Myers Squibb by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 134,058,636 shares of the biopharmaceutical company’s stock worth $6,079,559,000 after purchasing an additional 1,580,750 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Bristol-Myers Squibb by 6.7% during the 2nd quarter. BlackRock Inc. now owns 114,798,394 shares of the biopharmaceutical company’s stock worth $5,206,108,000 after purchasing an additional 7,178,698 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Bristol-Myers Squibb by 40.4% during the 2nd quarter. Invesco Ltd. now owns 24,012,686 shares of the biopharmaceutical company’s stock worth $1,088,974,000 after purchasing an additional 6,915,526 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Bristol-Myers Squibb by 67.6% during the 2nd quarter. Renaissance Technologies LLC now owns 20,698,607 shares of the biopharmaceutical company’s stock worth $938,682,000 after purchasing an additional 8,347,432 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of Bristol-Myers Squibb by 75.7% during the 2nd quarter. Janus Henderson Group PLC now owns 16,156,559 shares of the biopharmaceutical company’s stock worth $732,691,000 after purchasing an additional 6,960,047 shares during the last quarter. Institutional investors and hedge funds own 80.25% of the company’s stock.

Shares of BMY traded up $0.13 during mid-day trading on Wednesday, reaching $51.96. 185,804 shares of the stock traded hands, compared to its average volume of 10,084,974. The firm has a market cap of $84.42 billion, a price-to-earnings ratio of 13.05, a P/E/G ratio of 2.54 and a beta of 0.72. The stock has a fifty day simple moving average of $49.70 and a 200 day simple moving average of $47.13. Bristol-Myers Squibb Co has a 12-month low of $42.48 and a 12-month high of $59.28. The company has a quick ratio of 3.75, a current ratio of 3.88 and a debt-to-equity ratio of 1.51.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.12. The company had revenue of $6.27 billion for the quarter, compared to analyst estimates of $6.10 billion. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The business’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.01 earnings per share. On average, equities research analysts expect that Bristol-Myers Squibb Co will post 4.29 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be paid a dividend of $0.41 per share. The ex-dividend date is Thursday, October 3rd. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.16%. Bristol-Myers Squibb’s dividend payout ratio is currently 41.21%.

Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. set a $62.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Friday, September 13th. Atlantic Securities raised shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price target on the stock in a research note on Wednesday, August 14th. Bank of America raised their price target on shares of Bristol-Myers Squibb from $49.00 to $50.00 and gave the stock a “neutral” rating in a research note on Thursday, October 10th. TheStreet raised shares of Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a research report on Wednesday, September 18th. Finally, ValuEngine raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Monday, October 7th. Eight equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Buy” and a consensus price target of $55.81.

In related news, Director Robert J. Bertolini purchased 11,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was acquired at an average price of $44.72 per share, for a total transaction of $491,920.00. Following the completion of the purchase, the director now owns 11,397 shares in the company, valued at $509,673.84. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.13% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Further Reading: What causes a recession?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.